BamSEC and AlphaSense Join Forces
Learn More

First Tracks Biotherapeutics Inc. – Material Contracts

NASDAQ: TRAX    
Share price (7/7/26): $19.78    
Market cap (7/7/26): $690 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.8
from 10-Q 4 pages Amendment No. 1 to License Agreement
12/34/56
EX-10.7
from 10-Q 44 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Is the Type That First Tracks Biotherapeutics, Inc. Treats as Private or Confidential
12/34/56
EX-10.6
from 10-Q 12 pages Certain Personal Information in This Exhibit, Marked by [*], Has Been Redacted Pursuant to Item 601(a)(6) of Regulation S-K
12/34/56
EX-10.5
from 10-Q 12 pages Certain Personal Information in This Exhibit, Marked by [*], Has Been Redacted Pursuant to Item 601(a)(6) of Regulation S-K
12/34/56
EX-10.4
from 10-Q 12 pages Certain Personal Information in This Exhibit, Marked by [*], Has Been Redacted Pursuant to Item 601(a)(6) of Regulation S-K
12/34/56
EX-10.3
from 10-Q 17 pages Certain Personal Information in This Exhibit, Marked by [*], Has Been Redacted Pursuant to Item 601(a)(6) of Regulation S-K
12/34/56
EX-10.7
from S-1 7 pages First Tracks Biotherapeutics, Inc. 2026 Equity Incentive Plan Notice of Restricted Stock Unit Award
12/34/56
EX-10.6
from S-1 10 pages First Tracks Biotherapeutics, Inc. 2026 Equity Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.5
from S-1 22 pages Registration Rights Agreement
12/34/56
EX-10.4
from S-1 45 pages Certain Confidential Information Contained in This Securities Purchase Agreement Has Been Omitted by Means of Redacting a Portion of the Text and Replacing It With [***], Pursuant to Regulation S-K Item 601(b) of the Securities Act of 1933, as Amended. Certain Confidential Information Has Been Excluded From the Exhibit Because It Is: (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Securities Purchase Agreement
12/34/56
EX-10.3
from S-1 11 pages First Tracks Biotherapeutics, Inc. 2026 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1 23 pages First Tracks Biotherapeutics, Inc. 2026 Equity Incentive Plan
12/34/56
EX-10.1
from S-1 26 pages Transition Services Agreement Between First Tracks Biotherapeutics, Inc. and Anaptysbio, Inc. Dated April 20, 2026
12/34/56
EX-10.7
from DRS 7 pages First Tracks Biotherapeutics, Inc. 2026 Equity Incentive Plan Notice of Restricted Stock Unit Award
12/34/56
EX-10.6
from DRS 10 pages First Tracks Biotherapeutics, Inc. 2026 Equity Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.5
from DRS 22 pages Registration Rights Agreement
12/34/56
EX-10.4
from DRS 45 pages Certain Confidential Information Contained in This Securities Purchase Agreement Has Been Omitted by Means of Redacting a Portion of the Text and Replacing It With [***], Pursuant to Regulation S-K Item 601(b) of the Securities Act of 1933, as Amended. Certain Confidential Information Has Been Excluded From the Exhibit Because It Is: (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Securities Purchase Agreement
12/34/56
EX-10.3
from DRS 11 pages First Tracks Biotherapeutics, Inc. 2026 Employee Stock Purchase Plan
12/34/56
EX-10.2
from DRS 23 pages First Tracks Biotherapeutics, Inc. 2026 Equity Incentive Plan
12/34/56
EX-10.1
from DRS 26 pages Transition Services Agreement Between First Tracks Biotherapeutics, Inc. and Anaptysbio, Inc. Dated April 20, 2026
12/34/56